Prior research has evaluated and contrasted the long-term efficacy of individual SGLT2 inhibitors and SGLT2 inhibitors versus angiotensin receptor-neprilysin inhibitors in patients with heart failure [20]. The gene discussed is SLC5A2; the disease is heart failure.